Company intelligence / Profile preview

G

London, England, United Kingdom

Ownership: Private
Employees: ~70000
Development stage: Other

Overview

GSK has multiple marketed drugs and vaccines, including innovative therapies for HIV, respiratory infections, and vaccines (including adjuvanted and recombinant protein vaccines). Recent clinical success includes approvals in RSV and HIV, and ongoing pivotal studies in oncology and immunology[1][6].

Therapeutic areas: OncologyInfectious DiseasesPulmonology
Modalities: Small moleculeBiologicMonoclonal antibodyVaccineProteinRecombinant proteinAntibody
Industry: Pharma

Partnerships

Sanofi (vaccine development)Pfizer (ViiV Healthcare)ViiV Healthcare (HIV therapies subsidiary, joint with Pfizer and Shionogi)

Beyond the preview

Go deeper on G.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G.

Explore the full profile